Saitama, Japan

Kenji Sugibayashi

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Farnex Incorporated. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Sugibayashi. Retrieved from https://idiyas.com/inventor/kenji-sugibayashi-gqjaygjd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kenji Sugibayashi: Innovator in External Preparations

Introduction

Kenji Sugibayashi is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of external preparations that enhance drug permeability.

Latest Patents

Sugibayashi holds a patent for an external preparation comprising a non-lamellar liquid crystal-forming lipid. This innovative formulation is designed to be well retained on the surface of living bodies, thereby increasing the effectiveness of drug delivery.

Career Highlights

Kenji Sugibayashi is associated with Farnex Incorporated, where he applies his expertise in pharmaceutical innovations. His work focuses on creating advanced formulations that improve the therapeutic outcomes of various treatments.

Collaborations

Sugibayashi collaborates with Hiroaki Todo, contributing to the advancement of their shared goals in the pharmaceutical industry.

Conclusion

Kenji Sugibayashi's work exemplifies the impact of innovative thinking in the field of pharmaceuticals, particularly through his patented external preparation technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…